Changes in Hong Kong stocks | China Resources Pharmaceuticals (03320) rose more than 3%, China Resources Shuanghe, a subsidiary of China Resources, participated in the potential acquisition of part of Lier Chemical's shares

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that China Resources Pharmaceuticals (03320) rose more than 3%. As of press release, it had risen 2.8% to HK$4.77, with a turnover of HK$236.15,900.

According to the news, on July 15, China Resources Pharmaceutical announced that China Resources Shuanghe Pharmaceutical Co., Ltd. (China Resources Shuanghe), an indirect non-wholly-owned subsidiary of the company, has participated in the initiation of Sichuan Jiuyuan Investment Holding Group Co., Ltd. (Jiuyuan Group) and Sichuan Chemical Technology Co., Ltd. (Chemical Technology, together with Jiuyuan Group collectively known as the “seller”) to transfer the total holdings of Lier Chemical Co., Ltd. (Lier Chemical, a company listed on the Shenzhen Stock Exchange (stock code: 002258)), which accounts for 188,102,749 shares of Lier Chemical Approximately 23.50% equity (potential acquisition).

Lier Chemical is mainly engaged in R&D, production and sales of effective pesticide ingredients and pesticide formulations with high efficiency, low toxicity, low residue and safety. On July 15, 2026, China Resources Shuanghe received a notice from the seller confirming that it is the intended transferee ranked number one in the public collection and transfer method described above. As of the date of this announcement, China Resources Shuanghe did not hold any shares in Lear Chemical.

Since 2022, the Group has continued to deploy in the field of synthetic biology through China Resources Shuanghe. Currently, it has built seven major technology platforms, focusing on the four major fields of API intermediates, new health care foods, plant protection (pesticides, veterinary drugs, etc.), and new materials and new energy sources. The Company believes that the potential acquisition will meet the Group's overall strategic planning requirements and promote the industrialization of synthetic biological reserve technology products.